Immatics N.V. Warrants

IMTXW

Börsenwert 4.313 $

Profil: Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Mitarbeiter: 423